The Insider, Jay Barth Sold 30,000 Shares of Amicus Therapeutics, Inc. (FOLD), Profile of 3 Analysts Covering Edgewell Personal Care Co (EPC)

June 19, 2017 - By Michael Collier

After the disclosing of a legal document filled with Security and Exchange Commission; a trade became apparent. The Chief Medical Officer of Amicus Therapeutics Inc, Jay Barth; performed a transaction in the open market by selling 30,000 shares at an average cost of $10.0 of the Pinksheet-listed company having an approx. value of $300,000 USD. Currently, Mr. Jay, holds 64,184 shares, which accounts for 0.04% of the Company’s market cap.

Among 8 analysts covering Edgewell Personal Care Company (NYSE:EPC), 3 have Buy rating, 0 Sell and 5 Hold. Therefore 38% are positive. Edgewell Personal Care Company had 21 analyst reports since July 29, 2015 according to SRatingsIntel. Deutsche Bank maintained the shares of EPC in report on Monday, November 16 with “Hold” rating. The company was upgraded on Thursday, October 8 by Bank of America. The stock of Edgewell Personal Care Co (NYSE:EPC) has “Neutral” rating given on Wednesday, July 29 by Bank of America. Goldman Sachs upgraded Edgewell Personal Care Co (NYSE:EPC) on Monday, November 16 to “Neutral” rating. RBC Capital Markets maintained Edgewell Personal Care Co (NYSE:EPC) rating on Friday, June 2. RBC Capital Markets has “Buy” rating and $10500 target. Citigroup initiated the stock with “Overweight” rating in Monday, December 7 report. The stock of Edgewell Personal Care Co (NYSE:EPC) earned “Neutral” rating by UBS on Friday, February 3. The firm has “Hold” rating by Deutsche Bank given on Wednesday, November 18. Citigroup maintained the shares of EPC in report on Thursday, February 4 with “Buy” rating. Societe Generale initiated Edgewell Personal Care Co (NYSE:EPC) on Thursday, January 7 with “Hold” rating. See Edgewell Personal Care Co (NYSE:EPC) latest ratings:

02/06/2017 Broker: RBC Capital Markets Rating: Buy New Target: $105.0000 Maintain
03/02/2017 Broker: UBS Rating: Neutral Old Target: $82.00 New Target: $81.00 Maintain

Investors sentiment decreased to 1.24 in 2016 Q4. Its down 0.25, from 1.49 in 2016Q3. It dived, as 27 investors sold Amicus Therapeutics, Inc. shares while 32 reduced holdings. 25 funds opened positions while 48 raised stakes. 151.10 million shares or 5.89% more from 142.70 million shares in 2016Q3 were reported. Blackrock accumulated 11,836 shares or 0% of the stock. Commercial Bank Of New York Mellon holds 597,763 shares or 0% of its portfolio. Susquehanna Grp Inc Llp holds 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 40,473 shares. Spot Trading Ltd Llc holds 0% or 11,649 shares in its portfolio. California State Teachers Retirement Sys accumulated 293,438 shares or 0% of the stock. Nationwide Fund Advsr invested 0% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). 26,396 are owned by Principal Fincl Gp. Great West Life Assurance Can holds 0% or 10,300 shares. Metropolitan Life Ins reported 0% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Venbio Select Advisor Llc has invested 4.03% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Manufacturers Life Insurance The has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). The Massachusetts-based Wellington Management Group Llp has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Schwab Charles Inv Mgmt Inc owns 532,774 shares. Moreover, Victory Cap has 0.05% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD). State Board Of Administration Of Florida Retirement System has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 55,248 shares.

The stock increased 4.77% or $0.45 during the last trading session, reaching $9.88. About 5.49M shares traded or 93.31% up from the average. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 12.45% since June 19, 2016 and is uptrending. It has underperformed by 4.25% the S&P500.

Since December 22, 2016, it had 4 insider buys, and 5 selling transactions for $1.26 million activity. PERCEPTIVE ADVISORS LLC had bought 85,275 shares worth $410,050. Shares for $239,312 were sold by Do Hung. Campbell Bradley L sold $392,400 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Thursday, March 2.

Among 7 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Amicus Therapeutics has $28 highest and $8 lowest target. $14.50’s average target is 46.76% above currents $9.88 stock price. Amicus Therapeutics had 12 analyst reports since August 18, 2015 according to SRatingsIntel. The rating was upgraded by Janney Capital on Tuesday, March 8 to “Buy”. Bank of America initiated it with “Buy” rating and $10 target in Wednesday, May 18 report. The firm earned “Buy” rating on Tuesday, August 18 by Zacks. The firm earned “Neutral” rating on Thursday, April 14 by Robert W. Baird. The rating was maintained by Cowen & Co with “Buy” on Tuesday, September 1. On Monday, August 31 the stock rating was maintained by Leerink Swann with “Buy”. Chardan Capital Markets downgraded it to “Neutral” rating and $17 target in Wednesday, September 16 report. Chardan Capital Markets upgraded Amicus Therapeutics, Inc. (NASDAQ:FOLD) rating on Monday, October 5. Chardan Capital Markets has “Buy” rating and $8 target. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) has “Overweight” rating given on Tuesday, September 8 by JP Morgan. As per Wednesday, March 30, the company rating was initiated by Goldman Sachs.

Amicus Therapeutics, Inc. is a biotechnology company. The company has market cap of $1.51 billion. The Firm is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. It currently has negative earnings. The Company’s lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for Fabry disease.

Edgewell Personal Care Company is a maker and marketer of personal care products in the wet shave, sun and skin care, feminine care and infant care categories. The company has market cap of $4.36 billion. As of September 30, 2016, the Company had a portfolio of over 25 brands. It has a 23.94 P/E ratio. It manages its business in four divisions: Wet Shave, Sun and Skin Care, Feminine Care and All Other.

The stock increased 1.81% or $1.37 during the last trading session, reaching $76.94. About 443,502 shares traded. Edgewell Personal Care Co (NYSE:EPC) has declined 8.33% since June 19, 2016 and is downtrending. It has underperformed by 25.03% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: